5 Science Park
395 Winchester Ave
About Arvinas Inc.
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.
Designed with health and wellness in mind, employees and their families are eligible for:
- Medical, dental, and vision options, including a generous company contribution into an HSA
- Paid maternity and paternity leave
- FSA, HSA, Healthcare, and Dependent Care accounts
- Company provided life insurance and short/long-term disability coverage
- Additional voluntary benefits including critical illness, hospital care and more
COMPENSATION & EQUITY
Central to our organization is attracting, retaining and engaging the best and brightest by sharing in the success of our organization:
- Competitive salaries and an annual incentive program
- 401K matching program with immediate vesting
- Eligibility for long-term equity incentives upon hire and annually
We believe it’s important to relax, unwind and enjoy life’s moments:
- Paid vacation
- A year-end office closure
- Observed company holidays
- Paid sabbatical upon 5 years’ tenure
We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. We take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.
Working at Arvinas
116 articles about Arvinas Inc.
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers
Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit
Arvinas Inc.,, a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit.
Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, announced the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer.
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Bayer announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut.
4/5/2019Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC ARV-110 at ASCO 2018 Genitourinary Cancers Symposium
The studies show that degradation of the androgen receptor with ARV-110 leads to inhibition of AR target gene expression and the proliferation of prostate cancer cell lines.
Pfizer will use Arvinas' proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
ARV-378 is an orally bioavailable small molecule PROTAC designed to target and induce the degradation of the estrogen receptor protein, which plays a prominent role in the development of ER positive breast cancer.
Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Arvinas today announced the presentation of new preclinical data for its novel oral estrogen receptor alpha PROTAC program during a poster session at the 2017 SABCS.
Under the terms of the agreement, Arvinas will access Macroceutics' DNA-Encoded chemical Libraries to identify binders to multiple targets, which have been historically undruggable through protein inhibition.
Arvinas expanded an ongoing licensing deal with Genentech.
[02-November-2017] NEW HAVEN, Conn., Nov. 2, 2017 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the selection of its first candidate for clinical development as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC). ARV-110 is an orally bioavailable small molecu